Aurinia Pharmaceuticals Inc. AUPH
NASDAQ · United States · Health Technology
$16.20-0.23 (-1.37%)
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]
Activists also report to the SEC on Allot Communications, Genco Shipping & Trading, Aurinia Pharmaceuticals, and Turtle Beach.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.